Latest period
$1.08B
YoY change
+1076.3%
5Y CAGR
-4.9%
Peak year (2017)
$1.77B
Latest annual
$789.18M
Total Equity history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $789.18M
Total Equity growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: +1076.3%
Total Equity history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $789.18M | +1076.3% | +$722.09M | ||
| 2024 | $67.09M | -130.4% | +$287.73M | ||
| 2023 | −$220.64M | +39.5% | −$62.42M | ||
| 2022 | −$158.22M | -126.9% | −$746.43M | ||
| 2021 | $588.20M | -42.1% | −$428.04M | ||
| 2020 | $1.02B | -29.4% | −$422.44M | ||
| 2019 | $1.44B | +10.5% | +$136.73M | ||
| 2018 | $1.30B | -26.3% | −$464.47M | ||
| 2017 | $1.77B | +92.0% | +$846.21M | ||
| 2016 | $920.22M | -27.2% | −$344.49M | ||
| 2015 | $1.26B | +35.1% | +$328.45M | ||
| 2014 | $936.27M | +246.3% | +$665.92M | ||
| 2013 | $270.35M | +101.7% | +$136.29M | ||
| 2012 | $134.05M | +13.6% | +$16.06M | ||
| 2011 | $118.00M | -25.4% | −$40.24M | ||
| 2010 | $158.23M | -11.1% | −$19.73M | ||
| 2009 | $177.97M | -12.0% | −$24.16M | ||
| 2008 | $202.13M | +1.5% | +$2.96M | ||
| 2007 | $199.17M | -1.0% | −$2.01M | ||
| 2006 | $201.17M | +225.6% | +$139.40M | ||
| 2005 | $61.78M | +33.9% | +$15.64M | ||
| 2004 | $46.14M | -272.8% | +$72.85M | ||
| 2003 | −$26.71M | +474.8% | −$22.06M | ||
| 2002 | −$4.65M | — | — |
- 2025$789.18M+1076.3%
- 2024$67.09M-130.4%
- 2023−$220.64M+39.5%
- 2022−$158.22M-126.9%
- 2021$588.20M-42.1%
- 2020$1.02B-29.4%
- 2019$1.44B+10.5%
- 2018$1.30B-26.3%
- 2017$1.77B+92.0%
- 2016$920.22M-27.2%
- 2015$1.26B+35.1%
- 2014$936.27M+246.3%
- 2013$270.35M+101.7%
- 2012$134.05M+13.6%
- 2011$118.00M-25.4%
- 2010$158.23M-11.1%
- 2009$177.97M-12.0%
- 2008$202.13M+1.5%
- 2007$199.17M-1.0%
- 2006$201.17M+225.6%
- 2005$61.78M+33.9%
- 2004$46.14M-272.8%
- 2003−$26.71M+474.8%
- 2002−$4.65M—
Total Equity values are taken from Alnylam Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported total equity is $1.08B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Alnylam Pharmaceuticals (ALNY) total equity is $789.18M – surged 1076.3% year-over-year.
Over 2020–2025 (5 years), Alnylam Pharmaceuticals total equity expanded at a -4.9% compound annual rate, sustaining 2 straight years of year-over-year growth.
Between 2017 and 2025, Alnylam Pharmaceuticals total equity plunged 55.3%, falling from $1.77B to $789.18M.
The record annual total equity stands at $1.77B, reached in 2017; the historical low of −$220.64M was recorded in 2023.
Alnylam Pharmaceuticals Total Equity by Year
Alnylam Pharmaceuticals Total Equity 2025: $789.18M
In 2025, Alnylam Pharmaceuticals reported total equity of $789.18M, surged 1076.3% from 2024.
Alnylam Pharmaceuticals Total Equity 2024: $67.09M
Alnylam Pharmaceuticals total equity in 2024 was $67.09M, plunged 130.4% below 2023.
Alnylam Pharmaceuticals Total Equity 2023: −$220.64M
2023's total equity for Alnylam Pharmaceuticals came in at −$220.64M, surged 39.5% from 2022. This figure represents the lowest annual value in the available history.
Alnylam Pharmaceuticals Total Equity 2022: −$158.22M
Alnylam Pharmaceuticals posted total equity of −$158.22M in 2022, plunged 126.9% below 2021.
Alnylam Pharmaceuticals Total Equity 2021: $588.20M
Alnylam Pharmaceuticals total equity in 2021 was $588.20M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Total Equity
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation